^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Drug Class: | FLT3 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multi-Modal Targeting of FLT3 with Chimeric Antigen Receptor T Cell Immunotherapy and Tyrosine Kinase Inhibition in High-Risk Pediatric Leukemias
Published date:
11/04/2021
Excerpt:
Taken together, our preclinical studies demonstrate that dual targeting with FLT3CART immunotherapy and gilteritinib is a promising therapeutic strategy in FLT3-mutant AML and, importantly, also in KMT2A-R ALL.
DOI:
10.1182/blood-2021-147321
